Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.9%.
The iShares Biotechnology ETF (IBB) eased 0.2%.
In corporate news, enGene (ENGN) shares fell past 7% after UBS downgraded the stock to neutral from buy and cut its price target to $7 from $34.
Moderna (MRNA) reported a Q4 loss of $2.91 per share, worse than the $2.83 loss expected in a FactSet poll. Revenue was $966 million, better than the consensus estimate of $942.8 million. Its shares gained about 4%.
OS Therapies (OSTX) shares jumped 12%. The firm said it signed agreements for the commercial-ready manufacturing of OST-HER2 to support anticipated Biologics Licensing Authorization filing.
West Pharmaceutical Services (WST) shares popped past 7%. Deutsche upgraded the stock to buy from hold while lowering its price target to $250 from $275.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.